Yellow Carbon Dots (YC-Dots)

Yellow Carbon Dots

YC-Dots are derived from citric acid and 1,2-phenylenediamine prepared using a bottom-up approach mediated by ultrasonication. YC-Dots are highly biocompatible and have excitation-independent photoluminescence (max emission at 575 nm when excited at 400 nm). Morphology studies, including atomic force (AFM) and transmission electron microscopy (TEM), reveal that Y-CDs are spherical nanoparticles with a mean diameter of 3 nm.

Yellow Carbon Dots
Figure 2:   Images of Y-CDs (a) Solid (b) dispersed in water under room light (c) dispersion under UV light (360 nm)

Analytical spectroscopic techniques show that YC-Dots contain abundant functional groups such as carboxyl, amine, and hydroxyl groups on the surface. In addition, Y-CDs possess a high carbon content of 94%, which is rarely reported in other C-Dot species. YC-Dots have shown amphiphilicity, which allows them to cross various cell membranes and biological barriers such as the blood-brain barrier (BBB) for drug delivery.

Y-CDs have been used in research studies to enter the central nervous system (CNS) (in vivo, zebrafish model) while significantly inhibiting the expression of amyloid precursor protein (APP) and beta-amyloid (Aβ) inside cells (in vitro), which is of great significance towards the treatment of Alzheimer’s disease (AD).

Moreover, when YC-Dots were conjugated with small molecules, their amphiphilicity and capability to cross the BBB were not affected. Thus, YC-Dots have proved to be a promising versatile drug nanocarrier.

Although YC-Dots are more likely to be used in biological applications, the bright yellow photoluminescence drives the YC-Dots to use in day-to-day applications such as glow in dark parties.

Safety Information & Specifications

For the Material Safety Data Sheet for Yellow Carbon Dots, click here.


  1. S. Li, L. Wang, C. C. Chusuei, V. M. Suarez, P. L. Blackwelder, M. Micic, J. Orbulescu, R. M. Leblanc, Nontoxic Carbon Dots Potently Inhibit Human Insulin Fibrillation, Chem. Mater., 27 (2015) 1764-1771.
  2. Z. Peng, E. H Miyanji, Y. Zhou, J. Pardo, S. D Hettiarachchi, S. Li, P. L Blackwelder, I. Skromne, R. M. Leblanc, Carbon dots: Promising biomaterials for bone-specific imaging and drug delivery, Nanoscale, 9 (2017) 17533-17543.
  3. S. D. Hettiarachchi, R. M. Graham, K. J. Mintz, Y. Zhou, S. Vanni, Z. Peng, R. M. Leblanc, Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors, Nanoscale, 11 (2019) 6192-6205.
  4. Y. Zhou, P. Y. Liyanage, D. Devadoss, L. R. R. Guevara, L. Cheng, R. M. Graham, H. S. Chand, A. O. Al-Youbi, A. S. Bashammakh, M. S. El-Shahawi, R. M Leblanc, Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood–brain barrier and inhibitors of β-amyloid, Nanoscale, 11 (2019) 22387-22397.
  5. Y. Zhou, K. J Mintz, L. Cheng, J. Chen, B. C. L. B Ferreira, S. D Hettiarachchi, P. Y Liyanage, E. Seven, N. Miloserdov, R. R Pandey, B. Quiroga, P. L Blackwelder, C. C Chusuei, S. Li, Z. Peng, R. M Leblanc, Direct conjugation of distinct carbon dots as lego-like building blocks for the assembly of versatile drug nanocarriers, J. Colloid Interface Sci., 576 (2020) 412-425.
  6. P. Y. Liyanage, R. M. Graham, R. R Pandey, C. C Chusuei, K. J. Mintz, Y. Zhou, J. K. Harper, W. Wu, A. H. Wikramanayake, S. Vanni, R. M. Leblanc, Carbon nitride dots: A selective bioimaging nanomaterial, Bioconjugate Chem., 30 (2018) 111-123.
  7. A. Arumov, P. Y. Liyanage, A. Trabolsi, L. Li, E. R. Roberts, D. Bilbao, R. M. LeBlanc, J. H. Schatz, Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics, Blood, 134 (2019) 4061-4063.
  8. P. Y. Liyanage, Y. Zhou, A. O Al-Youbi, A. S. Bashammakh, M. S. El-Shahawi, S. Vanni, R. M. Graham, R. M. Leblanc, Pediatric glioblastoma target-specific efficient delivery of gemcitabine across the blood–brain barrier via carbon nitride dots, Nanoscale, 12 (2020) 7927-7938